Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873178 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1 | |
| SCHEMBL3873179 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL4665229 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL3878377 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL4639809 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL4665231 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL3878376 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL6133410 | 0.95 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL6133412 | 0.95 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL6604673 | 0.95 | ADRB3 (0.98) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404641-B1 | CRYSTALLINE FORM OF A PHENYLETHANOLAMINE, THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SANOFI AVENTIS (FR) | 2008-08-06 | — | — | EP | claimed |
| US-6992211-B2 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | SANOFI-AVENTIS (FR) | 2006-01-31 | — | — | US | claimed |
| US-20040180953-A1 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | claimed |
| EP-0626367-B1 | (7S)-7-(1R)-2-(3-chlorophenyl)-2-hydroethylamino-5,6,7,8-tetrahydronaphtalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them | SANOFI SA (FR) | 1997-04-09 | — | — | EP | claimed |
| US-5488151-A | {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino)-2-hydroxyethylamino]5,} acetic acid and its pharmaceutically acceptable salts | SANOFI (FR) | 1996-01-30 | — | — | US | claimed |
| JP-7070013-A | — | — | None | — | — | JP | disclosed |
| JP-7070013-A | — | — | None | — | — | JP | disclosed |
| EP-3024474-B1 | COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A BETA-3 ADRENERGIC RECEPTOR AGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10568927-B2 | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist | SERENITY PHARMACEUTICALS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180289769-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A BETA-3-ADRENERGIC RECEPTOR AGONIST | FIRST GENERATION CAPITAL INC. (CA) | 2018-10-11 | — | — | US | disclosed |
| US-9814753-B2 | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist | SERENITY PHARMACEUTICALS LLC (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160228452-A1 | TREATMENT OF METABOLIC DISEASES BY INHIBTION OF HTR2A OR HTR3 | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-08-11 | — | — | US | disclosed |
| US-6992211-B2 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | SANOFI-AVENTIS (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20040180953-A1 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| US-6284277-B1 | NONPROTEIN | SANOFI-SYNTHELABO (FR) | 2001-09-04 | — | — | US | disclosed |
| US-6118025-A | Method for preparing optically active α-substituted benzyl alcohols | SANOFI-SYNTHELABO (FR) | 2000-09-12 | — | — | US | disclosed |
| US-5488151-A | {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino)-2-hydroxyethylamino]5,} acetic acid and its pharmaceutically acceptable salts | SANOFI (FR) | 1996-01-30 | — | — | US | disclosed |
| US-5488151-A | {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino)-2-hydroxyethylamino]5,} acetic acid and its pharmaceutically acceptable salts | SANOFI (FR) | 1996-01-30 | — | — | US | disclosed |
| JP-H0770013-A | ((7S)-7-((2R)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YLOXY)ACETIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALT ACTING AS BETA 3-ADRENERGIC AGONISTS, PHARMACEUTICAL COMPOSITION AND LABORATORY REAGENT IN WHICH IT IS PRESENT | SANOFI SA | 1995-03-14 | — | — | JP | disclosed |
| JP-H0770013-A | ((7S)-7-((2R)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YLOXY)ACETIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALT ACTING AS BETA 3-ADRENERGIC AGONISTS, PHARMACEUTICAL COMPOSITION AND LABORATORY REAGENT IN WHICH IT IS PRESENT | SANOFI SA | 1995-03-14 | — | — | JP | disclosed |